Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaoncol.2024.0308 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Au@Pd Core-Shell Nanoparticles Conjugated to Panitumumab for the Combined β-Auger Electron Therapy of Triple-Negative Breast Cancer.
Int J Mol Sci
December 2024
Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195 Warsaw, Poland.
Apart from HER2-positive, triple-negative breast cancer (TNBC) is the second most highly invasive type of breast cancer. Although TNBC does not overexpress HER2 receptors, it has been observed that EGFR protein expression is present in this specific type of tumor, making it an attractive target for immune and radiopharmaceutical treatments. In our current study, we used Pd (T = 13.
View Article and Find Full Text PDFIntroduction: Locoregional recurrence (LR) is common in locally advanced head and neck cancer (HNSCC), posing challenges for treatment. We analysed outcome parameters and toxicities for patients being treated with radiotherapy (RT) for LR-HNSCC and investigated patient and disease related prognostic factors in this prognostically unfavourable group.
Methods: This analysis includes 101 LR-HNSCC patients treated with RT, radio-chemotherapy (RCT) or radio-immunotherapy (RIT) between 2010 and 2018 at a high-volume tertiary centre.
Antigen targeting and anti-tumor activity of a novel anti-CD146 Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.
Sci Rep
October 2024
Oncoinvent ASA, 0484, Oslo, Norway.
Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of a radioimmunoconjugate to locally target mesothelioma cancer cells has been proposed as a treatment. CD146, upregulated in mesothelioma but not in healthy tissues, is a promising therapeutic target.
View Article and Find Full Text PDFGold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors.
Nat Biotechnol
October 2024
Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
Strategies to enhance the anti-tumor immune response of stereotactic ablative radiotherapy (SABR) at primary tumors and abscopal sites are under intensive investigation. Here we report a metabolizable binary supracluster (BSC) that combines gold nanoclusters as radiosensitizing adjuvants with small interfering RNA (siRNA) targeting the immunosuppressive mediator galectin-1 (Gal-1). BSC comprises reversibly crosslinked cationic gold nanoclusters and siRNA complexes in a polymer matrix that biodegrades over weeks, facilitating clearance (90.
View Article and Find Full Text PDFMesoporous Microneedles Enabled Localized Controllable Delivery of Stimulator of Interferon Gene Agonist Nanoexosomes for FLASH Radioimmunotherapy against Breast Cancer.
ACS Appl Mater Interfaces
October 2024
The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People's Hospital, Yancheng, Jiangsu 224001, China.
Article Synopsis
- * Researchers used nanoexosomes (EXOs) delivered through porous microneedles to target and release a STING agonist (MSA-2) directly at the tumor site, enhancing treatment effectiveness while reducing side effects.
- * This method, combined with ultrahigh dose-rate FLASH irradiation, boosts immune responses and helps prevent tumor recurrence, showing potential for better managing both primary and metastatic tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!